Scynexis (SCYX) Income from Continuing Operations (2013 - 2026)
Scynexis (SCYX) reported Income from Continuing Operations of 16404000.0 for Q1 2026, down 204.28% on a YoY basis from 15729982.92 in Q1 2025, and down 233.82% quarter-over-quarter from 12258000.0 in Q4 2025.
Scynexis (SCYX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Scynexis has reported Income from Continuing Operations for 14 years, with the latest figure at 16404000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 204.28% year-over-year to 16404000.0; the trailing twelve-month figure through Mar 2026 stood at 19622000.0 (up 27.57% YoY), and the FY2025 full-year result was 8609000.0, up 59.56% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 16404000.0, down from 12258000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 122260000.0 in Q2 2023, with the low at 33876000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 2471882.35 across 5 years, with a median of 6885000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 4789.92% — and 2023, when it soared 1016.15%.
- Scynexis' Income from Continuing Operations stood at 14420000.0 in 2022, then slumped by 35.56% to 19548000.0 in 2023, then surged by 77.32% to 4433000.0 in 2024, then soared by 376.52% to 12258000.0 in 2025, then slumped by 233.82% to 16404000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 16404000.0 (Q1 2026), 12258000.0 (Q4 2025), and 8591000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Scynexis | 225.23 Mn | 165.97 Mn | - | -16.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.40 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -6.89 Mn |
| Mar 31, 2025 | -5.39 Mn |
| Dec 31, 2024 | -4.43 Mn |
| Sep 30, 2024 | -2.81 Mn |
| Jun 30, 2024 | -14.46 Mn |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | -19.55 Mn |
| Sep 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | 122.26 Mn |
| Mar 31, 2023 | -33.88 Mn |
| Dec 31, 2022 | -14.42 Mn |
| Sep 30, 2022 | -29.58 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -5.45 Mn |
| Dec 31, 2021 | -29.28 Mn |
| Sep 30, 2021 | -605,000.00 |
| Jun 30, 2021 | 1.66 Mn |